Latest available resultsQuarter ended June 30, 202610-Q · August 6, 2026
Filed with the SECZoetis Inc.
ZTSPharma & biotech
Next reportNovember 2, 2026pre-market · Analyst forecast 1.523 $/share
Revenue
$2.47B
▼ -0.2% vs prior year% YoY
Net income
$691.00M
▼ -4.8% vs prior year% YoY
EPS
1.65$
▲ +1.2% vs prior year% YoY
Net margin
28.0%
▼ -1.3 percentage points vs prior year pp YoY
Revenue▼ -0.2 %
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -4.8 %
EPS▲ +1.2 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $2.47B | |
| Gross profit | $1.79B | 72.7 % |
| Operating income | — | never filed |
| Net income | $691.00M | 28.0 % |
| R&D | — | never filed |
| EPS (diluted) | 1.65 $ | |
| Balance sheet | ||
| Assets | $15.08B | |
| Liabilities | $11.93B | |
| Equity | $3.15B | |
| Cash | $1.48B | |
| Capital | ||
| Shares outstanding | 413.22M | as of 2026-07-31 |
| Public float | — | |